News & Updates

A longer DTBT of up to 180 min is not associated with worse clinical outcomes at 30 days and 1 year in patients with STEMI presenting in Killip classes I–III, according to an analysis of data from the Singapore Myocardial Infarction Registry

Holding or decreasing the dose of outpatient beta blocker therapy does not seem to affect the incidence of tachyarrhythmias in patients with heart failure with reduced ejection fraction (HFrEF) admitted for acute decompensated heart failure (ADHF), reports a study.

People living with HIV (PWH) on statin therapy who have certain metabolic risk factors, such as obesity and prediabetes, are at greater risk of developing diabetes mellitus (DM), reports a study. This association is also present in those treated with placebo.

An analysis using the UK Biobank dataset shows a robust inverse association between well-being and risk of cardiovascular diseases (CVDs), underpinning the protective effect of higher well-being on the four major CVDs evaluated: coronary heart disease, MI, heart failure (HF), and stroke.

The oral fatty acid synthase (FASN) inhibitor denifanstat appears to produce meaningful improvements in metabolic dysfunction-associated steatohepatitis (MASH) and stage 2–3 fibrosis, as shown in the results of a phase IIb trial.

A 10-year study has found the association of salt sensitivity with insulin resistance and endothelial dysfunction in the offspring of hypertensive salt-sensitive parents, making them susceptible to developing hypertension.